{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T05:15:35Z","timestamp":1722834935202},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2008,6,1]],"date-time":"2008-06-01T00:00:00Z","timestamp":1212278400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AAPS J"],"published-print":{"date-parts":[[2008,6]]},"DOI":"10.1208\/s12248-008-9043-6","type":"journal-article","created":{"date-parts":[[2008,7,7]],"date-time":"2008-07-07T17:18:37Z","timestamp":1215451117000},"page":"363-372","source":"Crossref","is-referenced-by-count":16,"title":["Development, Validation, and Clinical Implementation of an Assay to Measure Total Antibody Response to Naglazyme\u00ae (Galsulfase)"],"prefix":"10.1208","volume":"10","author":[{"given":"Joleen T.","family":"White","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa Argento","family":"Martell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Van Tuyl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Warness","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary T.","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik","family":"Foehr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,7,8]]},"reference":[{"key":"9043_CR1","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1056\/NEJMoa011931","volume":"346","author":"N. Casadevall","year":"2002","unstructured":"N. Casadevall, J. Nataf, B. Viron, A. Kolta, J. J. Kiladjian, P. Martin-Dupont, P. Michaud, T. Papo, V. Ugo, I. Teyssandier, B. Varet, and P. Mayeux. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N. Engl. J. Med. 346:469\u2013475 (2002).","journal-title":"N. Engl. J. Med."},{"key":"9043_CR2","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s00415-006-0486-3","volume":"254","author":"H. P. Hartung","year":"2007","unstructured":"H. P. Hartung, C. Polman, A. Bertolotto, F. Deisenhammer, G. Giovannoni, E. Havrdova, B. Hemmer, J. Hillert, L. Kappos, B. Kieseier, J. Killestein, C. Malcus, M. Comabella, A. Pachner, H. Schellekens, F. Sellebjerg, K. Selmaj, and P. S. Sorensen. Neutralising antibodies to interferon beta in multiple sclerosis: expert panel report. J. Neurol. 254:827\u2013837 (2007).","journal-title":"J. Neurol."},{"key":"9043_CR3","first-page":"2428","volume":"83","author":"G. L. Bray","year":"1994","unstructured":"G. L. Bray, E. D. Gomperts, S. Courter, R. Gruppo, E. M. Gordon, M. Manco-Johnson, A. Shapiro, E. Scheibel, G. White III, and M. Lee. A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group. Blood. 83:2428\u20132435 (1994).","journal-title":"Blood"},{"key":"9043_CR4","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","volume":"68","author":"P. S. Kishnani","year":"2007","unstructured":"P. S. Kishnani, D. Corzo, M. Nicolino, B. Byrne, H. Mandel, W. L. Hwu, N. Leslie, J. Levine, C. Spencer, M. McDonald, J. Li, J. Dumontier, M. Halberthal, Y. H. Chien, R. Hopkin, S. Vijayaraghavan, D. Gruskin, D. Bartholomew, P. A. van der, J. P. Clancy, R. Parini, G. Morin, M. Beck, G. S. De la Gastine, M. Jokic, B. Thurberg, S. Richards, D. Bali, M. Davison, M. A. Worden, Y. T. Chen, and J. E. Wraith. Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology. 68:99\u2013109 (2007).","journal-title":"Neurology"},{"key":"9043_CR5","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2174\/1389201023378175","volume":"3","author":"E. Koren","year":"2002","unstructured":"E. Koren, L. A. Zuckerman, and A. R. Mire-Sluis. Immune responses to therapeutic proteins in humans-clinical significance, assessment and prediction. Curr. Pharm. Biotechnol. 3:349\u2013360 (2002).","journal-title":"Curr. Pharm. Biotechnol."},{"key":"9043_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jim.2004.06.002","volume":"289","author":"A. R. Mire-Sluis","year":"2004","unstructured":"A. R. Mire-Sluis, Y. C. Barrett, V. Devanarayan, E. Koren, H. Liu, M. Maia, T. Parish, G. Scott, G. Shankar, E. Shores, S. J. Swanson, G. Taniguchi, D. Wierda, and L. A. Zuckerman. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J. Immunol. Methods. 289:1\u201316 (2004).","journal-title":"J. Immunol. Methods"},{"key":"9043_CR7","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jpeds.2004.03.018","volume":"144","author":"P. Harmatz","year":"2004","unstructured":"P. Harmatz, C. B. Whitley, L. Waber, R. Pais, R. Steiner, B. Plecko, P. Kaplan, J. Simon, E. Butensky, and J. J. Hopwood. Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux\u2013Lamy syndrome). J. Pediatr. 144:574\u2013580 (2004).","journal-title":"J. Pediatr."},{"key":"9043_CR8","doi-asserted-by":"crossref","first-page":"e681","DOI":"10.1542\/peds.2004-1023","volume":"115","author":"P. Harmatz","year":"2005","unstructured":"P. Harmatz, D. Ketteridge, R. Giugliani, N. Guffon, E. L. Teles, M. C. Miranda, Z. F. Yu, S. J. Swiedler, and J. J. Hopwood. Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux\u2013Lamy syndrome): results after 48\u00a0weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase. Pediatrics. 115:e681\u2013e689 (2005).","journal-title":"Pediatrics"},{"key":"9043_CR9","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jpeds.2005.12.014","volume":"148","author":"P. Harmatz","year":"2006","unstructured":"P. Harmatz, R. Giugliani, I. Schwartz, N. Guffon, E. L. Teles, M. C. Miranda, J. E. Wraith, M. Beck, L. Arash, M. Scarpa, Z. F. Yu, J. Wittes, K. I. Berger, M. S. Newman, A. M. Lowe, E. Kakkis, and S. J. Swiedler. Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J. Pediatr. 148:533\u2013539 (2006).","journal-title":"J. Pediatr."},{"key":"9043_CR10","doi-asserted-by":"crossref","first-page":"7467","DOI":"10.4049\/jimmunol.178.11.7467","volume":"178","author":"J. A. Lofgren","year":"2007","unstructured":"J. A. Lofgren, S. Dhandapani, J. J. Pennucci, C. M. Abbott, D. T. Mytych, A. Kaliyaperumal, S. J. Swanson, and M. C. Mullenix. Comparing ELISA and surface plasmon resonance for assessing clinical immunogenicity of panitumumab. J. Immunol. 178:7467\u20137472 (2007).","journal-title":"J. Immunol."},{"key":"9043_CR11","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1373\/clinchem.2005.053272","volume":"51","author":"M. Moxness","year":"2005","unstructured":"M. Moxness, S. Tatarewicz, D. Weeraratne, N. Murakami, D. Wullner, D. Mytych, V. Jawa, E. Koren, and S. J. Swanson. Immunogenicity testing by electrochemiluminescent detection for antibodies directed against therapeutic human monoclonal antibodies. Clin. Chem. 51:1983\u20131985 (2005).","journal-title":"Clin. Chem."},{"key":"9043_CR12","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S1096-7192(03)00007-6","volume":"78","author":"D. Auclair","year":"2003","unstructured":"D. Auclair, J. J. Hopwood, D. A. Brooks, J. F. Lemontt, and A. C. Crawley. Replacement therapy in mucopolysaccharidosis type VI: advantages of early onset of therapy. Mol. Genet. Metab. 78:163\u2013174 (2003).","journal-title":"Mol. Genet. Metab."},{"key":"9043_CR13","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1080\/08035320510028139","volume":"94","author":"P. Harmatz","year":"2005","unstructured":"P. Harmatz, W. G. Kramer, J. J. Hopwood, J. Simon, E. Butensky, and S. J. Swiedler. Pharmacokinetic profile of recombinant human N-acetylgalactosamine 4-sulphatase enzyme replacement therapy in patients with mucopolysaccharidosis VI (Maroteaux\u2013Lamy syndrome): a phase I\/II study. Acta. Paediatr. Suppl. 94:61\u201368 (2005).","journal-title":"Acta. Paediatr. Suppl."}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-008-9043-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1208\/s12248-008-9043-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-008-9043-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T03:42:12Z","timestamp":1559619732000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1208\/s12248-008-9043-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["9043"],"URL":"https:\/\/doi.org\/10.1208\/s12248-008-9043-6","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,6]]}}}